CancerHLA-I: Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines

CancerHLA-I is a comprehensive web-based resource developed to study the role of HLA class-I alleles, neobinders, cytokines, and immune responses in cancer immunotherapy and patient survival. Web Server: https://webs.iiitd.edu.in/raghava/cancerhla1/ Citation Dhall, A., Patiyal, S., Kaur, H., & Raghava, G. P. S. (2023). Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines. Computers in Biology and Medicine, 165, 107594. https://doi.org/10.1016/j.compbiomed.2023.107594 About the Database CancerHLA-I was developed to help researchers and clinicians explore the relationship between genomic immune profiles and cancer patient survival. The platform integrates HLA-I alleles, neoantigen binders, cytokine expression, and clinical survival information across multiple cancer types. The database contains: 8346 cancer patients 20 cancer types 352 HLA class-I alleles 660,959 tumor-specific HLA-I neobinders 153 cytokines and immune markers Data were collected and processed from: TCGA TCIA